Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

phase 1 study, STC-004-CS-001, evaluated the safety, tolerability and pharmacokinetics of the candidate in single ascending dose (SAD) and multiple ascending dose (MAD) arms

Next Previous
Trial Profile

phase 1 study, STC-004-CS-001, evaluated the safety, tolerability and pharmacokinetics of the candidate in single ascending dose (SAD) and multiple ascending dose (MAD) arms

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STC 004 (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 07 Feb 2025 According to the SiteOne Therapeutics Media Release, results from this study reinforce the potential of STC-004 as a transformative, non-opioid solution for pain management, company focused on rapidly advancing STC-004 into Phase 2 trials in the second half of this year.
  • 07 Feb 2025 New trial record
  • 04 Feb 2025 Results presented in the SiteOne Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top